Viridian Therapeutics, Inc. VRDN Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s common stock, shares authorized (in shares)?
- Viridian Therapeutics, Inc. (VRDN) reported common stock, shares authorized (in shares) of $200M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s common stock, shares authorized (in shares) changed year-over-year?
- Viridian Therapeutics, Inc.'s common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $200M to $200M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s common stock, shares authorized (in shares)?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $200M to $200M.